EGFR-targeted therapies in the post-genomic era.
EGFR-targeted therapies in the post-genomic era.
复制标题
DOI：
10.1007/s10555-017-9687-8
复制
发表时间：
2017-09
期刊：
影响因子：
--
通讯作者：
Grandis JR
中科院分区：
文献类型：
--
作者：
Xu MJ;Johnson DE;Grandis JR
超过90%的头颈部癌症过度表达表皮生长因子受体（EGFR）。在不同的肿瘤类型中，EGFR过表达与较差的预后和结果相关。靶向EGFR的疗法包括单克隆抗体、酪氨酸激酶抑制剂、磷脂酰肌醇3-激酶（PI 3 K）抑制剂和反义基因疗法。很少有EGFR靶向治疗药物被批准用于临床。单克隆抗体西妥昔单抗是食品和药物管理局（FDA）批准的EGFR靶向治疗，但在临床试验中表现出适度的益处。人源化单克隆抗体尼妥珠单抗除在中国获批用于鼻咽癌外，还在古巴、阿根廷、哥伦比亚、秘鲁、印度、乌克兰、象牙海岸和加蓬获批用于头颈癌。例如，很少有其他EGFR靶向治疗头颈癌的药物能产生像肺癌那样显著的反应。最近对头颈部肿瘤的基因组测序有助于确定对EGFR抑制剂反应改善的患者亚组，例如西妥昔单抗用于KRAS变异患者，酪氨酸激酶抑制剂厄洛替尼用于携带MAPK 1 E322 K突变的肿瘤。基因组测序进一步拓宽了我们对失调途径的理解，有可能增强靶向EGFR治疗的获益。
Over ninety percent of head and neck cancers overexpress the epidermal growth factor receptor (EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer prognosis and outcomes. Therapies targeting EGFR include monoclonal antibodies, tyrosine kinase inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, and antisense gene therapy. Few EGFR-targeted therapeutics are approved for clinical use. The monoclonal antibody cetuximab is Food and Drug Administration (FDA) approved EGFR-targeted therapy, yet has exhibited modest benefit in clinical trials. The humanized monoclonal antibody nimotuzumab is also approved for head and neck cancers in Cuba, Argentina, Colombia, Peru, India, Ukraine, Ivory Coast and Gabon in addition to nasopharyngeal cancers in China. Few other EGFR-targeted therapeutics for head and neck cancers have led to as significant responses as seen in lung carcinomas, for instance. Recent genome sequencing of head and neck tumors has helped identify patient subgroups with improved response to EGFR inhibitors, for example cetuximab in patients with the KRAS-variant and the tyrosine kinase inhibitor erlotinib for tumors harboring MAPK1E322K mutations. Genome sequencing has furthermore broadened our understanding of dysregulated pathways, holding the potential to enhance the benefit derived from therapies targeting EGFR.
登录
查看更多内容
影响因子：
8.8
作者：
del Campo, J. M.;Hitt, R.;Sebastian, P.;Carracedo, C.;Lokanatha, D.;Bourhis, J.;Temam, S.;Cupissol, D.;De Raucourt, D.;Maroudias, N.;Nutting, C. M.;Compton, N.;Midwinter, D.;Downie, L.;Biswas-Baldwin, N.;El-Hariry, I.;Harrington, K. J.
通讯作者：
Harrington, K. J.
从头颈鳞状细胞癌的基因组研究中获得的治疗见解。
影响因子：
28.2
作者：
Hammerman PS;Hayes DN;Grandis JR
通讯作者：
Grandis JR
影响因子：
158.5
作者：
Bonner, JA;Harari, PM;Ang, KK
通讯作者：
Ang, KK
影响因子：
11.5
作者：
Chen, David J.;Nirodi, Chaitanya S.
通讯作者：
Nirodi, Chaitanya S.
影响因子：
3.3
作者：
GOLDMAN, CK;KIM, J;GILLESPIE, GY
通讯作者：
GILLESPIE, GY